Balancing Innovation and the Safe Introduction of Orthopedic Arthroplasty Implants to Market: The Ever‐Evolving Regulatory Environment in Australia
Journal of Orthopaedic Research · 2026
DOI: 10.1002/jor.70106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Orthopaedic Research, 2026. Verfasst von Joseph Femia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Orthopedic and Trauma Research, The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Device Approval, Prostheses and Implants. Die Arbeit nennt 76 Literaturangaben.
Abstract (Originalsprache)
The safe introduction of orthopedic medical devices remains a global priority due to high‐profile failures and evolving regulatory conditions. Recent reforms to regulatory requirements in Europe, the United States and Australia seek to strengthen both pre‐ and post‐market medical device evaluation. This perspective review outlines the current Australian regulatory environment with comparison to the European and United States systems, where arthroplasty devices must comply with Essential Principles, undergo Conformity Assessment, and be listed on the Australian Register of Therapeutic Goods. Evidence requirements include preclinical bench testing, computer simulations, clinical trial outcomes, national registry data and comparisons to existing implant designs demonstrating substantial equivalence. However, problems faced globally are inconsistent expectations across device types, fragmented advisory structures and vague mandatory criteria (open to interpretation), which makes designing studies today that will meet regulatory requirements years into the future difficult. Lessons from recent reforms, such as the European Union Medical Device Regulation and the United Kingdom's Beyond Compliance initiative, highlight the benefits of phased introduction, objective assessment criteria and real‐world data integration. While regulatory tightening improves patient safety, it also introduces risks of market consolidation and potential delays in access to innovation. The adoption of validated surrogate outcome measures in pre‐market assessment and post‐market surveillance studies, including national registry data, is vital to monitor potential implant failure mechanisms. A balanced, risk‐proportionate model is essential to support innovation while safeguarding public health and will enable multinational collaboration to enhance the quality of implants available to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Orthopedic and Trauma Research, The University of Adelaide, Adelaide, South Australia, Australia.
- Department of Orthopedics and Trauma, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Joseph Femia, Boopalan Ramasamy, Stuart Adam Callary
Zitieren
APA
Femia, J., Abrahams, J. M., Sandow, M., Solomon, L. B., Ramasamy, B., & Callary, S. A. (2026). Balancing Innovation and the Safe Introduction of Orthopedic Arthroplasty Implants to Market: The Ever‐Evolving Regulatory Environment in Australia. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.70106
Vancouver
Femia J, Abrahams JM, Sandow M, Solomon LB, Ramasamy B, Callary SA. Balancing Innovation and the Safe Introduction of Orthopedic Arthroplasty Implants to Market: The Ever‐Evolving Regulatory Environment in Australia. Journal of Orthopaedic Research. 2026. doi:10.1002/jor.70106
BibTeX
@article{Femia2026,
author = {Femia, Joseph and Abrahams, John Matthew and Sandow, Michael and Solomon, Lucian Bogdan and Ramasamy, Boopalan and Callary, Stuart Adam},
title = {Balancing Innovation and the Safe Introduction of Orthopedic Arthroplasty Implants to Market: The Ever‐Evolving Regulatory Environment in Australia},
journal = {Journal of Orthopaedic Research},
year = {2026},
doi = {10.1002/jor.70106}
}
EUVIMED